Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | NeuroPace, Inc: NeuroPace to Present at the Needham 23rd Annual Healthcare Conference | 1 | GlobeNewswire (USA) | ||
11.03. | NeuroPace shares target lifted to $17 by JPMorgan | 3 | Investing.com | ||
06.03. | Neuropace Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
05.03. | NeuroPace Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
05.03. | NeuroPace Inc - 10-K, Annual Report | 1 | SEC Filings | ||
05.03. | Recap: NeuroPace Q4 Earnings | 1 | Benzinga.com | ||
05.03. | NeuroPace, Inc.: NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million | 185 | GlobeNewswire (Europe) | -- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 -- -- Provides full-year 2024 revenue guidance... ► Artikel lesen | |
05.03. | NeuroPace Inc - 8-K, Current Report | 1 | SEC Filings | ||
22.02. | A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts | 1 | Benzinga.com | ||
15.02. | NeuroPace, Inc: NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 | - | GlobeNewswire (USA) | ||
07.02. | NeuroPace Inc - 8-K, Current Report | 1 | SEC Filings | ||
08.01. | NeuroPace stock soars on upbeat Q4 revenue guidance | 1 | Seeking Alpha | ||
08.01. | NeuroPace Inc - 8-K, Current Report | 1 | SEC Filings | ||
08.01. | NeuroPace, Inc: NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates | 298 | GlobeNewswire (Europe) | Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023 Company begins 2024 with cash balance... ► Artikel lesen | |
21.12.23 | NeuroPace, Inc.: NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study | 1.142 | GlobeNewswire (Europe) | NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently indicated... ► Artikel lesen | |
19.12.23 | NeuroPace, Inc.: NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 1 | GlobeNewswire (USA) | ||
04.12.23 | NeuroPace, Inc.: NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration | 146 | GlobeNewswire (Europe) | First of its kind, multi-year collaboration leverages RNS System's data to track responses of implanted RNS System patients enrolled in a biotechnology company's clinical trial In strategic data collaboration... ► Artikel lesen | |
04.12.23 | NeuroPace Inc - 8-K, Current Report | 1 | SEC Filings | ||
04.12.23 | Expert Ratings for NeuroPace | 1 | Benzinga.com | ||
01.12.23 | NeuroPace, Inc.: NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 37,480 | +0,70 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler nach erfolgreichem Geschäftsjahr 2023 weiterhin auf Wachstumskurs | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Jahresergebnis
Eckert & Ziegler nach erfolgreichem Geschäftsjahr 2023 weiterhin auf Wachstumskurs
22.03.2024 / 07:45 CET/CEST
Für... ► Artikel lesen | |
ORPEA | 10,220 | -0,25 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 22.03.2024 | The following instruments on XETRA do have their first trading 22.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 22.03.2024
Aktien
1 US05605F1049 BW LPG Ltd. ADR
2 CA27034B1085... ► Artikel lesen | |
NANO-X IMAGING | 9,760 | 0,00 % | Nano-X Imaging Q4 Earnings Preview | ||
BUTTERFLY NETWORK | 1,065 | 0,00 % | Butterfly Network erhält EU MDR-Zertifizierung für Butterfly iQ+ Geräte in europäischen Schlüsselmärkten | Das Unternehmen wird in den kommenden Monaten wichtige fortschrittliche neue Funktionen wie Pulswellen-Doppler und Auto-B-Line-Counter für die europäischen Butterfly iQ+-Geräte einführen. ... ► Artikel lesen | |
GOODRX | 7,100 | +1,28 % | Why GoodRx Surged Today | ||
JOINT CORP | 12,970 | 0,00 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
TRANSMEDICS GROUP | 71,00 | +2,90 % | TransMedics draws bullish view at Piper Sandler on valuation | ||
CARMAT | 4,010 | -2,67 % | CARMAT Announces a Final Agreement With All Its Financial Creditors on New Repayment Terms for Its Bank Loans | Final maturity of all bank loans extended by at least 2 years Equitization of the loan contracted with the EIB to reduce its repayment in cash and optimize the Company's cash position
Regulatory... ► Artikel lesen | |
HYPERFINE | 1,020 | +2,00 % | Hyperfine, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
PROGYNY | 38,300 | +0,82 % | Progyny executive chairman sells over $219k in company stock | ||
MIMEDX | 7,650 | +0,53 % | MIMEDX GROUP, INC. - 8-K, Current Report | ||
BIOMERICA | 0,898 | +0,91 % | Biomerica, Inc.: Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference | ||
ATRION | 412,00 | +2,49 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
ATRICURE | 30,360 | 0,00 % | AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug | ||
ENVVENO MEDICAL | 5,100 | +0,99 % | enVVeno Medical Corporation: enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity | Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO)... ► Artikel lesen |